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Abstract 
 
There is a widespread perception that pharmaceutical R&D is facing a productivity crisis 
characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D 
costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all 
R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. 
The empirical findings present an industry in transformation. In the first place, we observe a decline 
of the total number of publications by large firms. Second, we show a relative increase of their 
external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary 
base, in particular towards computation, health services and more clinical approaches. Also evident 
is a more pronounced decline in publications by both R&D laboratories located in Europe and by 
firms with European headquarters. Finally, while publications by Big Pharma in emerging economies 
sharply increase, they remain extremely low compared with those in developed countries. In 
summary, the trend in this transformation is one of a gradual decrease in internal research efforts 
and increasing reliance on external research. These empirical insights support the view that large 
pharmaceutical firms are increasingly becoming ‘networks integrators’ rather than the prime locus 
of drug discovery.  
 
Keywords: Pharmaceuticals, bibliometrics, outsourcing, Europe, globalisation, research network, 
innovation, collaboration 
 
Highlights 
 
 We analyse the publications by R&D laboratories of the top 15 pharmaceutical firms. 
 We observe a slow decline in their total number of publications and field share. 
 A more pronounced decline in publications by R&D laboratories located in Europe. 
 There is more external collaboration and research in non-traditional disciplines. 
 The results suggest that Big Pharma firms are increasingly network integrators.  
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1. Introduction 
 
Studies from a variety of sources and perspectives suggest that the pharmaceutical industry is facing 
a productivity crisis and is undergoing a substantial transformation. A stagnant or declining number 
of new chemical entities (NCE) are approved by regulators such as the US Food and Drug 
Administration (FDA) each year in spite of sustained, major increases of R&D expenditures (Munos, 
2009; Pammolli et al., 2011). In response, pharmaceutical firms have engaged in a series of major 
mergers with each other; undertaken waves of acquisitions involving smaller drug discovery firms; 
closed R&D sites, particularly in Europe and the US; sought cost savings through rationalisation 
(LaMattina 2011) and opened R&D laboratories in emerging countries with large markets such as 
India and China (Anon 2010). The industry is increasingly outsourcing R&D to external research 
organisations, which is perceived to improve efficiency (Baum 2010). Governments are supporting 
these trends by increasingly focusing public sector funding on ‘translational’ research (Collins 2011). 
 
In this paper we explore these shifts by studying changes in the publication activities of the world’s 
15 largest pharmaceutical firms in Europe and the US (‘Big Pharma’). Historically, the role of Big 
Pharma in the production of scientific research has been important, with a collective R&D 
investment of ~£46bn per annum between  2004-2007 (see Table 1) compared to an average annual 
spend of £15.25 by the US National Institute of Health (NIH) over the same period.2 As a result, the 
publication activity of these pharmaceutical firms is large (~10,000 document/year) and may be 
explored to trace changes in the industry.  Publication data does not provide direct insight into the 
R&D processes because a variety of factors shape and mediate propensity to publish, but as 
discussed in the next section when handled with care and contrasted with other data sources, 
publication rate and patterns may shed some light on dynamics in the quantity, areas and modalities 
of R&D efforts, and thus provide glimpses of the underlying processes of change processes of change 
(Tijssen, 2004, pp. 713–715). 
 
We will explore shifts in Big Pharma activity from three perspectives: How has the knowledge base 
of pharma changed? How has its organisational structure evolved? How have pharmaceutical firms 
relocated their R&D activities?  
 
First, in the cognitive sphere, the shift since the 1970-80s with the advent of biotechnology from a 
random-screening regime, towards a guided-search regime could be expected to make pharma R&D 
more reliant on basic biological research (McKelvey et al., 2004; Hopkins et al., 2007). However, the 
cumulative nature of competence acquisition by firms means that this process would be expected to 
occur in a progressive manner (Nightingale and Martin, 2004; Hopkins et al., 2007), rather than in a 
disruptive way (Hwang and Christensen, 2008). What do publications data tell us about the changes 
in the knowledge base? 
 
Second, at the organisational level, the interaction between emerging ‘biotech’ firms and 
pharmaceutical industry has been presented as the prototypical example of the organisational 
network as the ‘locus of innovation’ (Powell et al., 1996), with an estimate by UK drug developers 
that they outsource 25% of their R&D (Howells et al., 2008). Recent empirical research has also 
shown evidence for this shift in drug discovery. Munos (Munos, 2009, p. 965) showed that the share 
of the drugs approved by large firms in the US has steadily decreased from ~80% in 1980 to about 
~50% in 2008. Kneller (Kneller, 2010) reported that at least half of the new drugs discovered in the 
USA between 1998 and 2007 originated from public laboratories or small firms (see also (Angell, 
2004, pp. 52–73)).3 If this is the case, can we see an increase in the dependence of Big Pharma on 
                                                          
2
 The average per year is $28.5Bn - See NIH budget at http://www.nih.gov/about/director/budgetrequest/  
3 In the case of biotechnology-related patents the growth of small firms is even faster: from less than 15% in 
1990-94 to more than 35% in 2000-04, with big pharma shrinking from ~42% to ~31% (Patel et al., 2008). 
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external collaborations? Is there evidence of pharmaceutical R&D becoming less ‘R’ (research) and 
more ‘D’ (development)?  
 
Third, from a geographical perspective, the internationalisation of R&D either by off-shoring internal 
R&D or by outsourcing it using external collaborations, has received significant policy and media 
attention. The perceived relocation of pharmaceutical activities is often accompanied by stories of 
European weakness in comparison to the US  (Tijssen, 2009). Given the relative importance of the 
pharmaceutical industry in various European economies, and its position as one of the (few) high-
tech industries with a dominant European base, the potential decline of this sector has been a 
regular concern in the EU (e.g. see (Tijssen, 2009; Pammolli et al., 2011)). Do publications support 
the view of a European decline? Given the observation that interactions between publicly funded 
research and firms’ R&D efforts often take place in close geographical proximity, is this European 
decline also visible in Big Pharma’s collaborative links?  
 
Table 1. List of European and USA pharmaceutical firms included in this study. 
 
Firm Publications 
1995-2009 
Employees (2008) Mean R&D spent/year 
( 2004-2007 in M £) 
GlaxoSmithKline  19,331 101,133 3,186 
Novartis 15,477 96,717 3,604 
Hoffmann–La Roche 14,351 80,080 4,195 
AstraZeneca  11,378 66,100 2,740 
Sanofi-Aventis  11,211 98,213 3,722 
Bayer 8,125 107,299 2,270 
Novo Nordisk  3,378 31,062 837 
Boehringer Ingelheim  3,036 41,300 1,425 
Aggregate EU  84,863 621,904 21,979 
        
Pfizer 23,290 129,226 7,371 
Merck 21,697 106,200 4,540 
Eli Lilly 9,584 40,500 2,144 
Johnson & Johnson  7,197 118,700 4,576 
Abbott 6,482 69,000 1,440 
Bristol-Myers Squibb  6,349 35,000 2,016 
Amgen  5,070 16,900 1,908 
Aggregate USA 78,194 515,526 23,995 
Note: Publications include those of subsidiaries, acquisitions and parent firms of mergers. Source: 
2009 UK R&D Scoreboard (BIS, 2009)  
 
There is a lack of agreement among scholars about what R&D off-shoring to developing countries 
precisely entails (Ujjual et al., 2011). Due to the relatively distinct activities pursued in the stage of 
drug discovery (lab based) and drug development (clinically based) it may well be the case that R&D 
off-shoring takes place for some activities and not for others. Some scholars argue in this respect 
that there is a shift towards a globalisation of innovation, for example via externalisation of clinical 
trials to Contract Research Organisations (CROs) (Archibugi and Iammarino, 1999), whereas others 
suggest that local R&D centres are concerned with adaptation to local markets, for example by 
focusing on research on diseases that are prevalent in tropical areas or among certain population 
groups (von Zedtwitz and Gassmann, 2002). What do publications tell us about these alleged 
geographical shifts? 
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To our knowledge, this is the first large scale study of pharmaceutical publication trends. The only 
studies published previously are by Robert Tijssen, who showed trends of collaborative modes 
(Tijssen, 2004) or focused on the location of pharmaceutical R&D of European firms (Tijssen, 2009). 
Our analysis covers the world’s largest pharmaceutical firms and uses novel visualisation tools to 
intuitively convey to a non-expert audience the knowledge base of these firms (Rafols et al., 2010) 
and their collaboration networks (Perianes-Rodríguez et al., 2010). Data and bibliometric 
visualisations are made available in the Complementary Files listed in Appendix 1 and in a dedicated 
website.4  
 
Publications give only a partial view of a firm’s activities, and section 2 discusses the limitations of 
such a focus before describing in Section 3 the materials and methods employed to track the 
publications of large pharma. Section 4 provides a detailed analysis of publication output exploring 
each of the three areas outlined above. Section 5 provides discussion and conclusions where we 
emphasise that our empirical insights support the prevalent view that large pharmaceutical firms are 
increasingly becoming ‘networks integrators’ rather than the prime locus of drug discovery (Hirschler 
and Kelland 2010, Hopkins et al. 2007). 
 
2. The limitations of using publication data to track the R&D activity of Big Pharma 
 
Publications cannot be assumed to be a reliable proxy to describe the dynamics of research in a 
private firm, even in a science-based area such as pharmaceuticals. For example, the concerns raised 
over the scientific integrity of research conducted by pharmaceutical companies are likely to have 
affected publication strategies, especially in the clinical fields (e.g. (Angell, 2004; Smith, 2005)). As 
well as a decline in R&D, we also observe that pharmaceutical companies may face decreased 
legitimacy in science which may be reflected in their publishing patterns (Sismondo, 2009)   
(Sismondo 2009). Careful analysis is thus needed to make inferences from publication data. 
  
To understand how Big Pharma’s R&D activity differs from its publication activity, it is helpful to 
consider that publication activity has traditionally been associated with Open Science institutions. By 
Open Science we mean here a distinct organizational sphere where rapid disclosure of new research 
results and sharing of associated methods and materials is encouraged (David, 1998). Open Science 
should not be confused with Open Innovation (Chesbrough, 2003), a model in which firms develop 
innovation by sharing knowledge with a variety of non-profit and for-profit organisations –but 
without the knowledge being necessarily in the public domain. Open Science is based on the pursuit 
of priority, for example to claim credit for discovery and to hasten diffusion of knowledge, and as 
such encourages the rapid disclosure of research findings in scientific journals (Merton, 1973; 
Stephan, 1996). In contrast, firms often rely on secrecy and protective mechanisms such as patents 
to limit knowledge spillover risks and ensure returns to their investments (Dasgupta and David, 
1994), even if, they operate in an Open Innovation model. This implies that the contributions of Big 
Pharma to Open Science cannot be simply considered an unbiased reflection of their research efforts 
and their scientific discoveries. Rather, scientific publication activity in firms is not only driven by the 
pursuit of scientific reward but also by commercial interests and by pressures imposed on firms by 
prescribers, healthcare payers and regulators to disclose data. 
 
In the case of pharmaceutical research it is important to distinguish between the motivations firms 
have to publish during drug discovery and during drug development. With respect to the former, 
Hicks suggested that firms publish in order to ‘participate in the barter-governed exchange of 
scientific and technical knowledge’ and to send signals to investors (Hicks, 1995, p. 421). Adopting an 
Open Science strategy is in this case considered necessary in order to connect to the scientific 
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community and to access its resources in the form of knowledge, qualified labour and informal 
advice (Hicks, 1995; Cockburn and Henderson, 1998). Investments in R&D are in this context a 
means to create absorptive capacity which is necessary both to take advantage of (upstream) 
research conducted outside the organizational boundaries of pharmaceutical firms. The advent of 
biotechnology has been associated with an increase of explicit interaction between industry and 
academic science (McKelvey et al., 2004). Firm strategies have thus moved towards a more 
networked and Open Innovation model (Powell et al., 1996; Chesbrough, 2003), in which publishing 
is seen as positively associated with innovative success (Jong and Slavcheva, 2012). However 
whether Open Innovation leads to more Open Science is an open question. Indeed our results 
suggest the reverse. 
 
In drug development, it can be argued that incentives to publish are higher than in other science-
based industries, due to the highly regulated nature of drug development and the importance of 
clinical evidence for user uptake of innovations. Moreover, intellectual property will already be in 
place on the underlying compound before drug development, which limits the risks of free riders. 
Scientific publications are therefore primarily written to diffuse information about the effectiveness 
and safety of pharmaceuticals to a wide range of stakeholders. This process is especially incentivized 
in an evidence-based medicine paradigm (Timmermans and Berg, 2003; Montori and Guyatt, 2008) 
which is an attempt to ground medical decisions directly in available scientific evidence (e.g. clinical 
trials, systematic reviews). It follows that pharmaceutical firms make use of publications as 
marketing tools that need to be carefully constructed and employed in order to win support in 
regulatory or policy arenas (e.g. in to gain approval of clinical trials) and in clinical settings (e.g. 
credibility among doctors) (Smith, 2005; Sismondo, 2009). In drug development scientific 
publications are also used as competitive devices to promote the superiority of a compound vis-a-vis 
potential substitutes introduced by competitors (Polidoro and Theeke, 2011).  
 
While publications are therefore important in drug discovery and drug development, their analysis 
needs to be undertaken carefully because publications serve a variety of purposes.  Thus, changes in 
publication trends can reflect different underlying phenomena. For example, the propensity to 
publish may change when a firm shifts towards more science-based areas and wants to engage with 
academics (Hicks, 1995). Similarly, in drug development, publication may underestimate research in 
pharmaceutical firms if industrial scientists publish their own research using ‘ghost writers’, i.e. 
hidden behind the alleged authorship of academics (Sismondo, 2007).5 Moreover, some portion of 
research may be expected to be held back from publication for reasons of commercial secrecy, as 
discussed above.  
 
A final consideration is the extent to which tracking the publications of the 15 largest firms in an 
industry tells us about the industry as a whole. There are thousands of firms now engaged in 
pharmaceutical R&D. In comparison to Big Pharma these firms are either smaller or younger and 
some of them are engaged in non-traditional activities, for example biotech firms focusing on novel 
therapeutic modalities like cell therapies or RNA interference. While the sample here does not 
represent the industry as a whole, the firms tracked in this sample account for over 50% of the 
pharmaceuticals brought to market since 1950 (based on (Munos, 2009)) and hence represent the 
core of the traditional pharmaceutical industry. Furthermore because the publications tracked 
include those of firms acquired by Big Pharma over the studied period, the publications also 
incorporate the attempts by these firms to renew their capabilities. 
 
Given all these limitations, we conclude that the analysis of publications does not in itself reflect the 
dynamics of Big Pharma’s R&D. However, at the high level of aggregation we conduct this study 
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(based on about 10,000 publications per year in total, with around 150 to 1,500 publications per firm 
annually) it does raise interesting questions on R&D trends and firm strategies which then can be 
discussed in light of complementary quantitative evidence such as the trends revealed in studies 
using a variety of other metrics such as patents and pharmaceutical projects (Kneller, 2010; 
Pammolli et al., 2011). 
 
3. Materials and Methods 
 
The papers authored by staff at 15 major European and USA pharmaceutical firms were downloaded 
from Thomson-Reuter’s Web of Science (WoS). Complementary File 1 (URL embedded) lists the firm 
names used in retrieval, including subsidiaries, and merger and acquisition targets. Information on 
each firm’s acquisitions, mergers and subsidiaries was collected from their annual reports and the 
Recombinant capital database (http://www.recap.com/). The document types chosen were ‘article’, 
‘letter’, ‘note’, ‘proceeding paper’, and ‘review’ for the period 1995-2009.  A total of 160,841 records 
were obtained, standardised, processed and analysed with VantagePoint software 
(http://thevantagepoint.com/). Publications were classified as European when the affiliation 
contained at least one country in the European Union (EU) or in Switzerland, Norway, Lichtenstein 
and Iceland, i.e. the members of the European Free Trade Association (EFTA).  
 
The freeware programmes Pajek (http://pajek.imfm.si/) and VOSviewer 
(http://www.vosviewer.com/, (van Eck and Waltman, 2010)) were used for visualisation. A 
description of the methods used for maps is presented in Appendix 2. 
 
To compare our dataset of the publications of the top 15 pharmaceutical firms to the field of 
sciences relevant to pharmaceutical R&D in general, we made two baseline datasets. First, to look 
into number of organisations and authors per paper, publications of the top 200 journals in which 
pharma published were downloaded from WoS. Two thousand publications were randomly selected 
from these journals for the years 1995, 1999, 2004 and 2009 and this data was used as a baseline for 
Figure 5. Secondly, to investigate the relative change in the number of publications that list Big 
Pharma staff as authors per journal and field, the total number of publications for the period 1995-
2009 of the top 350 Journals in which Big Pharma published were downloaded from the Journal 
Citations Reports. This data was used as a baseline for Table 2. 
 
4. Results: Shrinking knowledge production  
 
Big Pharma has published over 10,000 publications per year in 1995-2009. This is a substantial 
contribution in the biomedical area, equals to about 4% of all publications in their field (estimated 
from the 350 journals where Big Pharma has the most publications). 
 
The first insight from this study is that Big Pharma have reduced the number of publications they 
produce by around 0.8% per annum when taking into account additional boosts to publication 
counts from subsidiaries and acquisitions prior to them joining their current parent. This amounts to 
a 9% decrease over 15 years, as shown in Figure 1. The results are a conservative estimate for the 
decrease, given that we are using full counting (i.e. without assigning fractions to co-authoring 
organisations) and collaborations are increasing over time (as discussed in section 4.2).  
 
This decrease is in stark contrast with R&D expenditure by large firms in the industry, which have 
increased in the order of 50% to 400% a decade (Arrowsmith, 2012, p. 18) and the general 
inflationary tendency in publication volumes  revealed in bibliometric studies of global scientific 
output (Persson et al., 2004; Leydesdorff and Wagner, 2009). In the areas where Big Pharma is 
publishing the most, we have estimated an annual growth rate of 1.1%, amounting to a 16% growth 
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over the period (again, estimated from the 350 journals where Big Pharma has the most 
publications). As a result, publications by Big Pharma show a relative decrease, from 5% of the total 
in the specialised pharma fields in 1995 to 4% in 2009. This slow decline is consistent with other 
studies apparently showing an absolute decline of patenting in pharmaceutical US patent classes 424 
and 514 (Subramanian et al., 2011, p. 68) and relative decline of patenting by big pharma in 
comparison to small firms in biotechnology (Patel et al., 2008, p. 51). 
 
However, if one looks at the publications by the core firms in our sample (defined as those with the 
name of the parent firm or of mergers), one observes a modest increase of 0.6%, totalling an 8% 
growth over the period. The difference between growth in publications by core firms and a decrease 
in all Big Pharma publications can be attributed partly to R&D outsourcing, and partly to closure, 
absorption and often rationalisation into the core firm of the R&D laboratories of the acquired firm. 
For example the former laboratories of firms such as Searle, Upjohn and Warner-Lambert were 
closed some time after their acquisition by Pfizer (LaMattina, 2011). Merck is estimated to have 
reduced its workforce by 30% after its merger with Schering-Plough in 2009 (McBride and Hollmer, 
2012). All the pharmaceutical industry (not just Big Pharma) is estimated to have reduced its 
workforce by 300,000 people since 2000 (Herper, 2011).  
 
 
Figure 1. Total number of publications per year of top 15 pharmaceutical firms. ‘Core firms’ 
includes only publications by R&D labs of the main firm or (or antecedents’ names) before a merger. 
‘Subsidiaries and Acquisitions’ includes the outputs published under the name of the acquired firms 
before and after the transaction. 
 
 
Figure 2 illustrates the wider dynamics of apparent core firm enlargement with overall R&D 
shrinkage in the case of the GlaxoSmithKline, which saw a sharp decrease in its aggregate number of 
publications in the aftermath of the merger of Glaxo-Wellcome and SmithKline Beecham in 2000. In 
the cases of Pfizer, Novartis and Bayer, a similar dynamic is observed for acquisitions. The only firm 
that shows significant growth in publications over the period is Johnson & Johnson. Data for each 
firm is available at Complementary File 2. 
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One can assume that the firms showing lower number of publications in relation to their R&D 
investment are also those with the highest degree of R&D outsourcing. For example,  Sanofi-Aventis, 
who has reduced its publications per year from ~1200 to ~400, report that ‘in Feb 2011, 64% of our 
development portfolio consisted of projects originated by external R&D’  (Sanofi-Aventis, 2010, p. 
17). AstraZeneca states that ‘We intend to increase our externalisation efforts to access the best, 
most cutting edge science, whatever its origin, with a target of 40% of our pipeline sources from 
outside our laboratories by 2014’ (AstraZeneca, 2010, p. 29).. It therefore appears that the 
outsourcing strategy is very actively being pursued by Big Pharma. 
 
 
Figure 2. Number of publications per year of GlaxoSmithKline, its subsidiaries, and the parent 
firms before merger. Year of merger or acquisition shown in brackets. See other firms in 
Complementary File 2. 
 
 
4.1 Cognitive shifts: Diversification of the knowledge base 
 
Next we examine the areas of research where Big Pharma is most active and how they changed over 
time. Figure 3 shows the distribution of the publications by Big Pharma over the global map of 
science (Rafols et al., 2010). 6 Each node represents a research field as defined by Web of Science 
Categories. The position and colours of the nodes is given by their relative similarity (strong 
similarity is shown with links). The size (area) of nodes shows the percentage of publications in that 
area. Figure 3 illustrates that the knowledge base of Big Pharma is centred on biomedical sciences 
(green nodes: Pharmacology and Pharmacy, Biochemistry and Molecular Biology), with some 
important contributions in Chemistry (in blue: Organic Chemistry and Medicinal Chemistry), 
Immunology and Infectious Diseases, and then a few smaller areas of Clinical Medicine (in red). Data 
is available at Complementary File 3, for the aggregate and for each firm. 
 
                                                          
 
 9 
 
Figure 4 shows the areas with positive (top) and negative (bottom) growth in publication numbers. 
The visualisation reveals a broad pattern of diversification, with a decrease in the traditional yet still 
dominant biomedical and chemical disciplines and an increase in peripheral areas related to new 
techniques (e.g. computational biology and related), and disciplines more oriented to clinical 
applications of therapeutics or health services.7 The latter observation is consistent with the 
observation that ‘industry has shifted resources away from drug discovery to late clinical 
developments’ (Munos and Chin, 2011, p. 1). For example, the proportion of pharma-biotech 
alliances in the pre-clinical stage decreased from 46% to 38% in 2007-2011, while those in marketed 
stage increased from 24% to 28% of the total (Ratner, 2012, p. 119). 
 
In the cognitive sciences, one also observes a move away from basic science (e.g. Neuroscience) and 
towards more applied fields (Psychiatry and Clinical Neurology). The decrease in publications related 
to plants and environment is possibly due to the externalisation of the agrochemical divisions from 
pharmaceutical firms. For example, Syngenta was created in 2000 when Zeneca and Novartis span 
out and merged their agrochemicals divisions. 
 
 
Figure 3. Distribution of publications by the top 15 pharmaceutical firms over the global map of 
science.  Nodes represent subject categories, with the area proportional to number of publications. 
The position of nodes is determined by similarity in citation patterns between the subject categories 
they represent.  
 
The growth of clinical areas such as oncology or rheumatology are consistent with data from 
pharmaceutical project data (Pammolli et al., 2011, p. 431). However, for other areas, such as 
cardiovascular, research output in terms of publications is slowly increasing (2.5% over 10 years) in 
                                                          
7 This diversification is captured by an increase in the Shannon-Wiener diversity (from 3.87 to 3.95). 
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spite of a substantial (-5%) decrease in the number of projects (Pammolli et al., 2011). Such apparent 
inconsistencies, though not surprising given variations in field definition and unit of analysis, warn 
against hasty interpretations of data.  
 
We also tried to visualise the specialisations of each firm using Web of Science publication data, but 
found Big Pharma had quite similar profiles at this coarse level of aggregation.8 In order to improve 
the granularity of description, we created a map based on the 191 journals that where Big Pharma 
publishes most frequently, available in Complementary File 4. See also interactive website: 
http://www.scimago.es/perianes/spru/Interaction_Companies.html. 
 
The results of the visualisation were mixed. These more granular maps (not shown in printed 
version) capture some of the specialisation patterns: for example, Eli Lilly’s focus on mental illness, 
or Novo Nordisk’s effort in endocrinology. However, the maps were less successful at showing the 
differences in focus between larger firms such as Pfizer, Novartis or Merck. This may suggest 
isomorphic pressures in the industry as leading firms are joined by fast followers into new 
therapeutic areas (DiMasi and Faden, 2011), which is quite likely given the industry’s reputation for 
producing ‘me-too’ drugs (Angell, 2004, pp. 74–93)). However, we believe that this might also signal 
the need for new analyses requiring more sophisticated approaches, for example using keywords 
such as the Medical Subject Heading (MeSH) provided by PubMed (Leydesdorff et al., 2012). 
 
The overall picture is that Big Pharma’s is reducing research in areas of traditional core expertise, 
namely in biomedical and chemistry areas, while at the same time diversifying into areas such as 
computational biology and fields that are closer to the patient (or perhaps market) such as health 
services and clinical research. However, as Big Pharma moves into new fields it relies more on 
external collaborations, as discussed in the next section.   
 
  
                                                          
8 A previous study had shown no effect of these small field differences between firms on innovation 
performance  (D’Este, 2005, p. 37). 
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Figure 4. Growth rate (top) and decrease rate (bottom) of publications by pharmaceutical firm in 
different scientific subject categories. Area of nodes is proportional to the growth (decrease) in 
publications. Only subject categories with more than 0.5% of the total publications are shown. 
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4.2 Organisational shifts: Increasing collaborations and out-sourcing 
 
The number of collaboration in science has been steadily increasing for decades (Hicks and Katz, 
1996; Wuchty et al., 2007). This trends towards ‘team science’ has been particularly pronounced in 
the biological sciences, medicine and neuroscience (Porter and Rafols, 2009, p. 730). Our data shows 
that such trends are even stronger in Big Pharma, but there is a twist: although Big Pharma is 
collaborating more, it is their partners that are more often taking the intellectual lead in the work 
that follows from such collaborations. 
 
Figure 5 illustrates the increase of the number of authors and the number of organisations per 
article for pharmaceuticals in comparison with a sample of papers (baseline) in related fields (2,000 
publications per year of analysis randomly extracted from the 200 top journals of pharma 
publication).9 Not only are pharmaceutical papers more collaborative, but their co-authorships are 
growing faster than average in the fields in which they publish. 
 
The extent to which Big Pharma collaborations are increasingly led by the external partners is shown 
in Table 2. There is a significant decrease in the percentage of Big Pharma-based first authors in 
collaborative publications (from 43% to 35%), and of Big Pharma-based corresponding authors (from 
41% to 34%) over the period studied.   
 
This trend is more prominent in the fields and journals into which Big Pharma has more recently 
entered (arguably those where new competences are more likely to be demanded), in contrast to 
the fields and journals where Big Pharma is shrinking its publication output (which are those of 
traditional core expertise). In the fields with increasing output, the share of Big Pharma 
corresponding authors decreased from 44%- to 36% in 1998-2009 (and from 47% to 39% in the ten 
fastest growing). In the case of areas with declining output, the share of pharma’s corresponding 
authorship remained quite stable, declining only from 52% to 49% (from 52% to 48% in those 
declining fastest). Likewise, the percentage of corresponding authors in growing journals decreased 
from 52% to 47% (from 70% to 60% in ten fastest growing), whereas the percentage in shrinking 
journals only declined marginally from 51% to 49% (from 51.2% to 50.5% in ten fastest shrinking). 
The inertia in the maintenance of the core expertise and the difficulty in catching up with new fields, 
is a general characteristic of firm dynamics given the cumulative nature of firms technological 
competences (Patel and Pavitt, 1997; Hopkins et al., 2007). 
 
The overall picture is consistent with a trend towards R&D outsourcing, driven by pressures to seek 
cost efficiencies (Baum, 2010).  Outsourcing entails a reduction of internal R&D laboratory capacity 
and the parallel expansion of alliance networks with small firms and academic laboratories (Powell 
et al., 1996), in which Big Pharma is an intellectual follower rather than a leader. This does not 
necessarily imply that Big Pharma’s ability to capture value from these alliances is reduced –
therefore, the implications of this shift will need further study.  
 
                                                          
9
 The increase in collaborations occurs both in ‘small’ and ‘big science’: a doubling or trebling in collaborations 
is observed both for very big teams (6 to 10 organisations, or 20 to 40 authors), and for large-scale projects (>20 
organisations and >40 authors).  
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Figure 5. Trends in collaborative practices in pharma R&D publications, compared to control 
publications in the same scientific fields (baseline). 
 
Table 2. Trends in scientific leadership in co-authored publications  
Year  1998(1) 2002 2006 2009 
% publications with external collaboration 62.1% 67.6% 69.1% 71.7% 
% organisations collab. baseline (estimate) 55.0% 59.0% 63.2% 66.4% 
      
Pharma-based first author  43.1% 38.4% 36.2% 35.0% 
      
Pharma-based corresponding author 40.7% 36.6% 35.0% 33.6% 
 In expanding fields2) 43.9% 38.9% 35.9% 35.6% 
 In shrinking fields(2) 52.3% 50.1% 50.5% 48.8% 
     
Pharma corresp. author (top 350 journals) 
50.8% 46.5% 47.3% 47.0% 
 In expanding journals 52.4% 48.0% 48.1% 46.6% 
 In shrinking journals 50.9% 46.4% 47.6% 48.8% 
Notes: (1) Data starts in 1998 due to partial missing data in WoS on corresponding and first authors in 1995-
1997. (2) Since some journals are assigned to various fields (Web of Science Categories), this figure is a slight 
overestimate.  
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4.3 Geographical shifts 
 
4.3.1 The decline of Big Pharma’s European R&D  
 
It has been suggested that European pharmaceutical firms have weakened over recent decades 
(McKelvey et al., 2004). The trends confirm such decline both in terms of the publications of all 
European R&D laboratories, shown in Figure 6, left, including European labs of American firms, such 
as Pfizer’s site at Sandwich, UK (which has closed since this data was collected, illustrating the point), 
and of all laboratories of firms with European headquarters (shown in Figure 6, right, including USA 
labs of European firms). Beyond the decline in number of publications, European-headquartered 
firms have also decreased the proportion of publications that they lead, as shown by number of 
corresponding authors, from 45% to 35% (Figure 6, right), whereas US-based firms have undergone a 
less marked decline (from 52% to 47%). Geographical data discussed in this section is available in 
Complementary File 5. 
 
Figure 7 shows that the decline of Big Pharma’s European publications has been concentrated in the 
UK, Switzerland and France. In contrast, Big Pharma firms have maintained their German publication 
output and increased their output in smaller European countries such as Sweden, Belgium and 
Denmark. 
 
Part of the European decline may be attributed to the fact that whereas Europe-based firms have 
located an important share of their R&D activities in USA laboratories (producing about 35% of their 
publications), USA-based firms on the other hand have a smaller presence in Europe (producing only 
22% of their publications). This is illustrated in Figure 8 (left).  
 
Such imbalances in the USA versus European presence of Big Pharma has been previously well 
documented, e.g. by studies on publications (Tijssen, 2009) and patent inventors (Friedman, 2010; 
Pammolli et al., 2011). In the latter case, patent concentration in the home continent of the firm is 
even more acute, as shown in Table 3. These data should be taken as conservatives estimates of 
home country bias because in this study publication data counts the publications of acquired firms 
with the parent firm –which means that acquisitions explain a very important proportion of the non-
home publications of firms. For example, Roche’s large percentage of USA publications is partly 
explained by its acquisition of Genentech; or Johnson and Johnson’s large European presence is 
largely due to its Belgian subsidiary Janssen.  
 
 
 
Figure 6. Publications by location of pharmaceutical R&D laboratories (left). Publications by 
locations of firm headquarters (right), for all publications (top) and for those with Big Pharma 
affiliations for the corresponding author (bottom).  
 
 15 
 
Although in most of this analysis we adopt a Europe versus USA comparative perspective, a more 
careful analysis of the data reveals that European pharmaceutical companies are still remarkably 
national (or bi-national as a results of mergers in the case of AstraZeneca and Sanofi-Aventis) (see 
Table 3). Outside their home countries, European firms have more publications from US-based labs 
than all their non-domestic European labs (i.e. Europe excluding the ‘home country’ of the firm). 
Such is the extent of the national base for collaborations that when co-authorships are mapped into 
organisational networks there are striking similarities to the natural geographic distribution of 
countries, as shown in Figure 9, with Big Pharma playing a notable role spanning the bibliometric 
equivalent of the ‘Atlantic’.  
 
 
Figure 7. Location of pharmaceutical R&D laboratories authoring papers 
 
 
 
 
Figure 8. Location of pharmaceutical R&D laboratories (left) and external collaborators (right) for  
Big Pharma headquartered in Europe vs. the USA.  
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One recurrent argument of why European (or Japanese) pharmaceutical firms locate R&D centres in 
the US, is that American basic biomedical research is of higher quality than European research (e.g. 
see (McKelvey et al., 2004))10. Given this argument, it seems paradoxical that although USA-based 
firms have much less R&D in Europe than their EU-based counterparts, both USA and European-
based firms have a very similar percentage of their total publications with external collaborators 
from across the Atlantic (about 40%). Given that the vast majority of these external collaborators are 
public research organisations, one can argue that in pharmaceutical research European public 
research is probably not so bad after all.  Alternatively it may reflect that the strategic interest of 
USA-based firms in the European pharmaceutical market is equal to the interest of European-based 
firms in the USA pharmaceutical market, as local collaborations are needed to prepare drug launches 
in those markets. Given this interest, scientific activities may well be employed across the Atlantic 
for marketing reasons, patient availability and proximity to regulators and medical practitioners. The 
rapid increase in clinical trial activities in Central and Eastern European countries may also be a 
reason for this.   
 
Table 3. Comparison between ‘Home country’ and regional location of research in 1995-2009.  
 
  % of Publications % 
Patents(2) 
Firm Home  
Country 
Home  
Country 
Europe(1) USA Rest of  
World 
 by US 
inventors 
USA Firms    
Pfizer USA See USA 24.2 75.6 3.4 81 
Merck USA See USA 24.3 71.0 8.3 88 
Eli Lilly USA See USA 19.9 81.7 3.9 n.a. 
Johnson & Johnson  USA See USA 33.9 65.7 4.7 86 
Abbott USA See USA 22.7 77.0 1.8 90 
Bristol-Myers Squibb  USA See USA 7.2 93.0 2.0 90 
Amgen  USA See USA 3.2 94.4 3.8 n.a. 
Aggregate USA   76.8 22.0 76.8 4.8  
European Firms    
GlaxoSmithKline  UK 44.5 15.8 43.9 2.4 47 
Novartis Switzerland 41.1 21.6 40.2 4.4 26 
Hoffmann–La Roche Switzerland 24.4 17.6 50.8 10.7 46 
AstraZeneca  UK & Sweden 77.7 3.7 19.4 3.4 19 
Sanofi-Aventis  Fran. & Germ.(3) 63.5 11.5 23.9 5.3 20 
Bayer Germany 62.2 6.8 29.2 5.7 n.a. 
Novo Nordisk  Denmark 87.5 4.3 9.1 2.3 n.a. 
Boehringer Ingelheim  Germany 40.8 17.2 34.9 14.7 n.a. 
Aggregate Europe(4)   51.5 14.0 35.7 5.4 n.a. 
Aggregate Europe     63.3 35.7 5.4 n.a. 
Notes: (1) In this table, ‘Europe’ excludes the home country in the case of European firms. (2) Source: 
Pammolli et al. (2011, p.434). Based on location of pharmaceutical firms’ inventors on patents from 1980-2004. 
(3) The headquarters of Sanofi-Aventis are in France, but during the period under study one of its antecedent 
                                                          
10
 There is a parallel discussion on the higher quality of US research in relation to other industries (Dosi et al., 
2006). 
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companies, Hoechst, had its headquarters in Germany. (4) This European aggregate is based on the sum of 
European firms. It includes double counting (estimated at 2.5%) due to collaboration between firms.  
 
 
 
Figure 9. Collaboration network of pharmaceutical firms. Different countries are distinguished by 
shade colour. Ovals only indicate approximate position of national clusters. 
 
4.3.2 Limited globalisation – so far. 
 
If there is a decline of European R&D associated with off-shoring and outsourcing of R&D, is there 
evidence of an increase in publications of R&D in emerging countries? The answer, for now, is 
certainly not a resounding yes. The percentage of Big Pharma publications outside of USA and 
Europe has remained stable and low, increasing only from about 500 to about 650 publications per 
year over the period 1995-2009, although in relative terms these publications have increased from 
4% to 6% of Big Pharma’s total. Most of these publications (~60-70%) originate in advanced 
economies such as Japan and Canada. Following investments in R&D centres (“Evolving R&D for 
emerging markets,” 2010) countries such as Singapore, India and China show rapid growth in 
publications, but  start from a very low base. The absolute number of publications emerging from Big 
Pharma’s new eastern R&D laboratories is still very low.  As shown in Figure 10, with the exception 
of Singapore, all other countries still have less than 20 publications/year on average, compared with 
~200 in Italy or ~600 in Switzerland.11  
 
In contrast, emerging countries are much more important contributors to publication activity when 
focusing on the external collaborators of Big Pharma. Whereas in 1998, only 10% of Big Pharma 
                                                          
11
 The numbers are so low that one wonders if research carried out in R&D laboratories in emerging countries is 
published with affiliations of the headquarter laboratories. Such practice has been observed in patents. 
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collaborators were from outside of Europe or the USA, this figure increased to 15% by 2009. This 
growth is partly due to the growing importance of universities in developed economies such as 
Canada and Australia (35% and 17% of ‘rest of the world’ collaborative publications in 2009, 
respectively). However, part of the increase is also due to the rapid increase in the collaborations 
between Big Pharma and public research organisations in countries such as China (157 publications 
in 2009), Brazil (98), South Korea (75), India (57) and Singapore (55). These collaborations are mainly 
between local public research organisations and R&D labs of Big Pharma in other countries. As 
shown in Table 4, co-location of local research organisations and local Big Pharma R&D labs does not 
appear to be the driver behind the increase of Big Pharma’s collaborative publications by emerging 
countries as these account for only the minority of collaborations that Big Pharma have with authors 
in the countries listed. 
 
A more plausible explanation for the increasing collaboration of pharma with emerging economies is 
the rapid globalization of clinical research activities (Thiers et al., 2008; Petryna, 2009). The conduct 
of large scale clinical trials requires the involvement of many patients and this renders a division of 
labour between those researchers that manage trials, design the study and analyze the data, and 
(clinical) investigators that enrol patients for data analysis. It is the latter’s activity that is increasingly 
conducted in emerging economies and in this case relations between pharmaceutical companies and 
clinical investigators from these countries are often mediated by a third party such as a Contract 
Research Organizations (CROs). The increase in external collaborators in emerging economies may 
therefore be a reflection of the increase of CROs. It is in this context likely that the observed 
publication activity of emerging economies is an underestimation of actual activity, because 
authorship for publication mainly accrues to researchers with scientific leadership and less often to 
the researchers that are actually engaged with patients in this type of clinical work (Hoekman et al., 
2012). 
 
In summary, publication data raises questions about the extent to which the opening of R&D centres 
in emerging economies such as India or China constitute a globalisation of pharmaceutical R&D –in 
the sense of making these new centres ‘competitors’ to those in the developed countries. The small 
number of publications from Big Pharma labs in these countries is consistent with relatively small 
units of 70 to 300 researchers in most cases (Ujjual et al., 2011), but also suggests these R&D labs 
are so far fulfilling other purposes, in particular an adaptation of their products to the emerging 
markets. These include: (i) research on issues specific to human and physical geographies such as 
tropical diseases or genetic susceptibilities; (ii) development of low cost drugs to cater for the 
medical needs in terms of cost and dosage of developing country populations; (iii) establishment of 
links with CROs conduction clinical trials, as well as broadening the genetic make-up of clinical trial 
populations (iv) presence in large markets with growing wealth and its associated medical needs, e.g. 
diabetes, cardiovascular complications (“Evolving R&D for emerging markets,” 2010; Ujjual et al., 
2011, p. 22).  
 
Since the globalisation of pharmaceutical R&D centres is a recent phenomenon and sustained 
publication activity takes time, there is the possibility that publication counts do not capture the 
most up-to-date trends. Singapore, the emerging country with most publications, saw the 
investment in new pharma labs (Lilly, Novartis, Pfizer) in the early 2000s, whereas most centres in 
China have only opened since the mid 2000s (Roche in 2004; Pfizer and Sanofi-Aventis in 2005; GSK 
and AstraZeneca in 2007; Novartis, 2008; Lilly and Johnson and Johnson in 2009; source: (“Evolving 
R&D for emerging markets,” 2010)).  
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 Figure 10. Location of Big Pharmas’ pharmaceutical R&D laboratories and collaborators in 
emergent countries. 
 
 
Table 4. Collaborations between local research organisations and local R&D labs of Big Pharma in 
emerging countries. The figures indicate the percentage of Big Pharma’s publications in a country 
carried out in collaboration with local external partners. 
 
Country  
% of Big Pharma’s collaboration in the 
country with local external partners  
1995-99 2000-04 2005-09 
India 19% 36% 26% 
Singapore 11% 18% 19% 
China 6% 4% 13% 
South Korea 4% 13% 13% 
Brazil 17% 9% 13% 
South Africa 15% 9% 4% 
 
 
5. Discussion: Causes and consequences of Big Pharma’s retreat from Open Science 
 
This paper has analysed the publication output of 15 largest pharmaceutical firms in Europe and the 
USA, including publications by all acquisition targets of these firms in the period 1995-2009, which 
represents the core of the traditional pharmaceutical industry – Big Pharma. The analysis suggests 
that these firms are undergoing a shift away from the open science activities associated with drug 
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discovery and towards a systems integrator role (Munos 2009; Paul et al. 2010; Pammolli, Magazzini, 
and Riccaboni 2011; Hopkins et al. 2007). 
 
Our empirical data provides some evidence of this shift from three perspectives. In the first place, a 
diversification of the knowledge base away from the traditional expertise in chemistry and biology 
towards computation, health services and more clinical fields. This diversification may be 
characterised crudely as a shift from basic towards clinical research, from research to development, 
or from bench towards bedside. Such a shift might be resulting from technological opportunities 
created by information technologies (Nightingale, 2000; Bonaccorsi, 2008), as the outcome of socio-
economic pressures in medicine towards practices that are more sensitive to the patient’s context or 
individual needs (Amir-Aslani and Mangematin, 2010) and/or of management strategies to reduce 
the financial risk associated with drug discovery (Munos and Chin, 2011)12. 
 
Second, to access these new areas of knowledge we observe an increase in external collaborations 
and of external leadership of co-authored papers, suggesting a tendency to outsource, in agreement 
with industry reports of increasing externalisation of R&D efforts (Baum, 2010; Hirschler and Kelland, 
2010). Such trends are consistent with the view that the locus of innovation is shifting from in-house 
R&D to small firms and public organisations (Munos, 2009; Kneller, 2010) or to the organisational 
network (Powell et al., 1996), in agreement with the Open Innovation model (Chesbrough, 2003). 
However these expanding collaborations are increasingly intellectually led by external collaborators 
rather than by big pharma themselves. Whether this has any implications for big pharma’s ability to 
capture value from these relationships remains to be explored.  
 
Third, from a geographic perspective, we find a more pronounced decline in publications by Europe-
based big pharma (including their USA labs) as well as a decline in total output of their European labs 
(including those owned by US firms), in comparison to all big pharma labs located in the US or all 
labs owned by USA firms. The relative decline in European laboratories is not uniform, with Germany 
resisting the trend, while the UK, France and Switzerland succumb most. Sweden, Denmark and 
Belgium buck the trend entirely. The shift away from undertaking internal R&D in Europe does not 
detract from the importance of European collaborators for Big Pharma – with European 
collaborators apparently as important to USA-based Big Pharma as US collaborators are to Europe-
based Big Pharma. 
 
Finally, while publications by Big Pharma in emergent countries have sharply increased, from a low 
base over the period studied, these remain extremely low compared with those in developed 
countries. Publishing activity in these R&D centres in developing countries have so far a small 
‘research’ component and a larger ‘development’ component, possibly associated with adaptation 
to local growing markets and coordination of clinical research that is outsourced to local CROs or 
public centres (Hoekman et al., 2012). 
 
The overarching tendency according to which we should judge these trends is one of a slow decline 
of the total number of publications by Big Pharma, in stark contrast with the inflationary tendencies 
of most bibliometric indicators in the period (Persson et al., 2004). This confirms earlier suggestions 
of a publication decline from corporate laboratories, inferred from a shorter period (1996-2001) and 
only for certain collaborative modes (Tijssen, 2004).  Based on our empirical data we can merely 
argue that there seems to be a shift away from an Open Science strategy in Big Pharma, which might 
be due to either a decrease of R&D performed in-house by  pharma (possibly due to increased R&D 
outsourcing), or a decrease in the propensity to publish. As carefully argued by Tijssen (Tijssen, 2004, 
pp. 726–727), one cannot rule out the possibility that Big Pharma is conducting the same or greater 
amount of R&D, but just publishing less –for example, because academic collaborators refrain from 
                                                          
12 See (Pammolli et al., 2011) for an opposite view on risk taking. 
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mentioning industrial involvement or because of fears of knowledge leaking out before patenting. Or 
it could also be that the retreat from publishing activities is due to a combination of increasing costs 
in the business of medical writing, heightened awareness by medical journals of the ‘marketing’ 
function of pharma articles and/or in the wake of scandals following ethically dubious practices such 
as ghost writing (Smith, 2005; Sismondo, 2009). 
 
However, industry analysts report of have observed R&D laboratories closures (LaMattina, 2011), 
decrease of R&D expenditure in comparison to sales (from the traditional 15-20% to ~10%  (Petsko, 
2011, p. 3)), outsourcing of R&D (Baum, 2010; Hirschler and Kelland, 2010), relative reduction of 
research in comparison to development (Jensen, 2010) and a drop by half in number of new 
pharma-biotech alliances (Ratner, 2012). This strongly suggests that pharma’s in-house R&D efforts 
are decreasing significantly. In fact, the decline in publication trends shown in Figure 1 might be a 
gross underestimate of the degree of in-house R&D reduction, because of increasing co-authorship 
trends observed during the period.   
 
In any case, either of these (perhaps complementary) interpretations tells of a decline in the 
importance of Open Science consistent with the idea that pharmaceutical companies are 
increasingly ‘network integrators’ instead of the prime locus of drug discovery (Subramanian et al., 
2011). As the chief executive of GlaxoSmithKline explains: 
 
‘Big Pharma players can no longer hope to generate the absolutely best science in all areas 
on their own. Therefore, rebuilding the R&D Engine in Big Pharma standard operating 
procedure should be to decide on a scientific bet (for example, kinases in oncology), shop 
around among all the external players that are pursuing such research, and establish a 
contractual relationship with the best.’ (Garnier, 2008, pp. 75–76) 
 
In doing so, Big Pharma is following other high-tech sectors, such as various firms in semiconductors 
and information technologies in the retreat from corporate R&D (Tijssen, 2004; The Economist, 
2007) Instead of being the R&D engine, Big Pharma, as network integrator, is possibly taking on the 
role of financier, regulatory liaison, lobbyists and salesman for publicly funded medical research 
because they have the resources, expertise and social capital to navigate the increasingly complex 
environment of health business, regulations and politics.  
 
The move away from Open Science (sharing of knowledge through scientific conferences and 
publications) is compatible and consistent with the increasing importance of Open Innovation 
(increased sharing of knowledge –but not necessarily in the public domain). More specifically, Big 
Pharma is not merely retreating from publication activities but in doing so it is likely to substitute 
more general dissemination of research findings in publications for more exclusive direct sharing of 
knowledge with collaboration partners. Hence, the reduction in publication activities - next to R&D 
cuts and lab closures – is indicative of a shift in Big Pharma’s knowledge sharing and dissemination 
strategies. 
 
Putting this view in a broader historical perspective, one can interpret the retreat of Big Pharma 
from Open Science, as the recognition that science (unlike specific technological capabilities) was 
never a core competence of pharmaceutical firms (Pisano, 2006) and that publication activity  
required a lot of effort, often without generating the sort of value expected by shareholders. When 
there are alternatives ways to share knowledge with partners, e.g. via Open Innovation agreements, 
these may be attractive. Indeed an associated benefit of this process is that Big Pharma can shield 
itself from scrutiny in the public domain by shifting and distributing risk exposure to public research 
organisations and small biotech firms. 
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Whether the retreat from R&D and the focus on system integration is a desirable development 
depends on the belief in the capacities of big pharma to coordinate and integrate these activities for 
the public good. At this stage, one can only speculate on the implications of Big Pharma’s retreat 
from Open Science. In a linear view of innovation where high-quality scientific activity results in new 
compounds, Big Pharma’s lack of investment in in-house science (or at least in genuine high risk 
research) can be seen as the cause of its R&D productivity crisis (Munos and Chin, 2011). However 
one can easily reverse this argument by stating that R&D cuts are just the consequence of the crisis: 
higher R&D costs and expiring patents (or anticipation of these events) lead to lack of investment 
which results in a shortage of capital to keep R&D.13  
 
Any discussion of the causality chains in Big Pharma’s apparent structural transformation will be 
complex and is beyond the scope of this study. An understanding of the industry evolution would 
require an analysis not only of corporate R&D activities, but of the interplay of financial markets, 
emerging economies, increased regulatory stringency, demographic changes resulting in new types 
of diseases to be addressed, technologies used in drug discovery, and changes in health provision 
triggered by welfare cuts. We nevertheless speculatively advance two debates where the retreat of 
Big Pharma from Open Science will figure centrally. 
 
The first debate concerns the capability of Big Pharma to carry out the role of system integrator in 
light of a reduction of its scientific base. It has been argued that over time science-based knowledge 
is becoming more important in drug discovery, and that firms therefore need to develop absorptive 
capacity by interacting with academia and small biotechs in order to acquire this knowledge 
(Cockburn and Henderson, 1998). This begs the question how Big Pharma will be able to screen and 
select the areas in which it will invest if it keeps reducing its in-house research. The apparent answer 
appears to be for academia to step in by doing ‘translational research’ and setting up private-public 
centres that facilitate Open Innovation’(West and Nightingale, 2009; Collins, 2011). The viability of 
this model is however unproven. 
 
The second debate concerns how the redistribution of research efforts will or should affect the 
redistribution of the social benefits and economic returns derived from drugs. Some observers have 
seriously questioned the economic returns enjoyed by Big Pharma in the last 20 years (Angell, 2004; 
Mazzucato, 2011, p. 96), in particular given the crucial contributions already made by public research 
(McMillan et al., 2000) and the forthcoming increases (Collins, 2011). Reuters’ analysts have put it 
eloquently (Hirschler and Kelland, 2010, p. 9): 
 
‘Drug companies have long promoted the idea that they pursue new drugs for the good of 
humanity; it's an argument Big Pharma regularly uses to justify the huge profits it makes. 
High returns, the industry argues, can be ploughed back into research on the next medical 
breakthrough. If Big Pharma is not doing the research itself, will the big margins be harder to 
defend?’ 
 
The use of the term defend here is ambiguous and could be interpreted as morally defend, or even 
defend against appropriation by partner organisations. The latter point features extensively in 
debates on the commercialization of scientific research  which question profitability  and raise the 
prospect of alternative forms of R&D network structures (Vallas and Kleinman, 2008).  
 
In conclusion, the analysis of Big Pharma’s publications over a 15 years period has provided us with a 
window on what may be early signs of a transformation in the pharmaceutical industry, driven by a 
‘perfect storm’ of pressures to change (Staton, 2011). Multidimensional studies weaving observed 
change in the knowledge base with financial, regulatory and social trends will be needed to put the 
                                                          
13 We thank Ed Steinmueller for this point. 
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findings of this paper in perspective and to think through future scenarios in health provision 
(Crommelin et al., 2010). 
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Appendix 1: List of complementary files 
 
Available at: www.interdisciplinaryscience.net/pharma  
 Complementary File 1: List of firm’s subsidiaries, acquisitions and mergers 
 Complementary File 2: Publication trends by firm 
 Complementary File 3: Web of Science Categories (WCs) of publication 
 Complementary File 4: Specialisation science maps: aggregate and by firm 
 Complementary File 5: Publication and collaboration trends by region and country  
The authors are willing to share further materials upon request. 
 
Appendix2: Methods for the generation of scientometric maps 
 
Two types of maps were created to visualize the knowledge base of pharmaceutical firms and one 
type for the collaboration networks. The first type (shown in Figures 3 and 4) was an overlay map of 
global pharma publications following the methodology detailed in Rafols et al. (2010a). An updated 
map based on 2009 version of the Global Map of Science was used to map category cross-citations.14 
The second type (used for 2 analyses) mapped the 191 most cited journals by the pharmaceutical 
firms in the period 1995-2009 (shown in Complementary File 4). All citations received by these 191 
journals were downloaded from the WoS. This data was used to create the cosine similarity measure 
between journals, which allowed location of the papers in a network according to Pajek’s Kamada-
Kawai algorithm. Factor analysis was applied to the resulting matrix to attribute each journal to a 
scientific speciality (e.g. Oncology) (Leydesdorff & Rafols, 2009; Perianes-Rodríguez et al., 2010).  
 
As described in the following section, this journal map was used to make two overlays for 
specialization of given pharmaceutical firms. The third type of map is a co-authorship network of the 
pharmaceutical firms and the top 50 collaborations of each of them (which have major overlaps), 
leading to a total of 286 organisations. The standard VOSviewer similarity measure was used to 
generate the spatial coordinates to set the relative position of organisations. Finally, the network 
was created in Pajek combining the matrix of co-authorship (edges) and the coordinates imported 
from VOSviewer (nodes). 
 
                                                          
14 This basemap is freely available at http://www.leydesdorff.net/overlaytoolkit/. 
